PYREFIN
Pyrefin is a development-stage pharmaceutical company focused on producing EP2 receptor antagonists. The drugs Pyrefin is testing have myriad potential uses, including treatment for epileptic seizures. Rodent trials have shown efficacy in treatment for seizure-induced brain injury, endometriosis, and osteoarthritis without behavioral or organ toxicity after 30 days. Phase 1A of GRAโs venture development support focused Pyrefinโs team on prioritizing the clinical use of its treatment.
PYREFIN
Industry:
Biotechnology Life Science Pharmaceutical
Status:
Active
Total Funding:
100.64 K USD
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical companyย focused on theย prevention and treatment of gastrointestinal disorders.
Current Employees Featured
Founder
Investors List
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Pyrefin
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Pyrefin